An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

ClinicalTrials.gov ID: NCT00403481

Public ClinicalTrials.gov record NCT00403481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Study identification

NCT ID: NCT00403481
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 192 participants

Conditions and interventions

Conditions

Hypertension

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2006 (Type not available)
Primary completion: Nov 2007 (Actual)
Completion: Dec 2007 (Actual)
Last update posted: Nov 3, 2016

2006 – 2007

United States locations

U.S. sites: 27
U.S. states: 19
U.S. cities: 27

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	—	—
Not listed	Mesa	Arizona	—	—
Not listed	Searcy	Arkansas	—	—
Not listed	Los Angeles	California	—	—
Not listed	Roseville	California	—	—
Not listed	Tustin	California	—	—
Not listed	DeLand	Florida	—	—
Not listed	Pembroke Pines	Florida	—	—
Not listed	Chicago	Illinois	—	—
Not listed	Wichita	Kansas	—	—
Not listed	Madisonville	Kentucky	—	—
Not listed	Auburn	Maine	—	—
Not listed	Baltimore	Maryland	—	—
Not listed	Oxon Hill	Maryland	—	—
Not listed	Jackson	Mississippi	—	—
Not listed	Florissant	Missouri	—	—
Not listed	Williamsville	New York	—	—
Not listed	Charlotte	North Carolina	—	—
Not listed	Winston-Salem	North Carolina	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	New Talenwell	Tennessee	—	—
Not listed	New Tazewell	Tennessee	—	—
Not listed	Colleyville	Texas	—	—
Not listed	Corpus Christi	Texas	—	—
Not listed	Richardson	Texas	—	—
Not listed	Murray	Utah	—	—
Not listed	Norfolk	Virginia	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00403481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 3, 2016 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00403481 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →